`
`
`DOCUMENTS CONSIDERED BY MICHAEL MAYERSOHN, PH.D.
`
`
`
`
`
`DOC. NO.
`
`DOCUMENT DESCRIPTION
`
`1
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`U.S. Patent No. 7,932,268 (Rader)
`
`U.S. Patent No. 8,618,135 (Rader)
`
`“Bayer/PPD Implitapide Development Follows Zetia Model As
`Statin Add-On,” The Pink Sheet, 66(7):17 (February 16, 2004)
`
`Stein Presentation re Microsomal Triglygeride Transfer Protein
`(MTP) Inhibitor (implitapide) program (2004)
`
`Chandler et al., “CP-346086: an MTP inhibitor that lowers
`plasma cholesterol and triglycerides in experimental animals
`and in humans,” Journal of Lipid Research, 44:1887-1901
`(2003)
`
`Chang et al., “Microsomal triglyceride transfer protein (MTP)
`inhibitors: Discovery of clinically active inhibitors using high-
`throughput screening and parallel synthesis paradigms,”
`Current Opinion in Drug Discovery & Development, 5(4):562-
`570 (2002)
`
`Shiomi & Ito, “MTP inhibitor decreases plasma cholesterol
`levels in LDL receptor-deficient WHHL rabbits by lowering the
`VLDL secretion,” European Journal of Pharmacology,
`431:127-131 (2001)
`
`Wetterau et al., “An MTP Inhibitor that Normalizes
`Atherogenic Lipoprotein Levels in WHHL Rabbits,” Science,
`282:751-754 (1998)
`
`Rowland & Tozer, Clinical Pharmacokinetics: Concepts and
`Applications, 57, 98 (1995)
`
`Certified U.S. Provisional Patent Application No. 60/550,915
`
`“Half-Year Pharma Operating Highlights,” The Pink Sheet,
`62(31):19-20 (July 31, 2000)
`
`1
`
`CFAD Ex. 1030 (1 of 2)
`
`
`
`Petition for Inter Partes Review of USPN 7,932,268
`
`
`DOC. NO.
`
`DOCUMENT DESCRIPTION
`
`12
`
`13
`
`Mayersohn, “Principles and Applications of Pharmacokinetics,”
`Medical Toxicology, 282- 337 (2004)
`
`Margaret A. McDowell et al., “Anthropometric Reference Data
`for Children and Adults: U.S. Population, 1999-2002,” CDC
`Advance Data from Vital & Health Stats., 361 (2005).
`
`
`
`
`
`2
`
`CFAD Ex. 1030 (2 of 2)